These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10687970)

  • 21. FGFR3 mutation analysis in voided urine samples to decrease cystoscopies and cost in nonmuscle invasive bladder cancer surveillance: a comparison of 3 strategies.
    van Kessel KE; Kompier LC; de Bekker-Grob EW; Zuiverloon TC; Vergouwe Y; Zwarthoff EC; Steyerberg EW
    J Urol; 2013 May; 189(5):1676-81. PubMed ID: 23142690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical model of cost of bladder cancer in the elderly.
    Cooksley CD; Avritscher EB; Grossman HB; Sabichi AL; Dinney CP; Pettaway C; Elting LS
    Urology; 2008 Mar; 71(3):519-25. PubMed ID: 18342201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.
    Hutterer GC; Karakiewicz PI; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Serretta V; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Perrotte P; Lotan Y; Marberger MJ; Shariat SF
    BJU Int; 2008 Mar; 101(5):561-5. PubMed ID: 18257856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for malignancy after augmentation cystoplasty in children with spina bifida: a decision analysis.
    Kokorowski PJ; Routh JC; Borer JG; Estrada CR; Bauer SB; Nelson CP
    J Urol; 2011 Oct; 186(4):1437-43. PubMed ID: 21855939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study.
    Daniltchenko DI; Riedl CR; Sachs MD; Koenig F; Daha KL; Pflueger H; Loening SA; Schnorr D
    J Urol; 2005 Dec; 174(6):2129-33, discussion 2133. PubMed ID: 16280742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder.
    Gupta NP; Sharma N; Kumar R
    Urology; 2009 Mar; 73(3):592-6; discussion 596-7. PubMed ID: 19168205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings.
    Bergman J; Reznichek RC; Rajfer J
    BJU Int; 2008 Jan; 101(1):26-9. PubMed ID: 17850364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression.
    Holmang S; Johansson SL
    J Urol; 2002 Apr; 167(4):1634-7. PubMed ID: 11912378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost of bladder tumour treatment and follow-up.
    Hedelin H; Holmäng S; Wiman L
    Scand J Urol Nephrol; 2002; 36(5):344-7. PubMed ID: 12487738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Telomerase activity as marker of superficial tumor of the bladder].
    Arias Fúnez F; Fernández Fernández E; Escudero Barrilero A; Moyano Jato A; Caso Peláez E
    Arch Esp Urol; 2000 Apr; 53(3):231-6. PubMed ID: 10851728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma.
    Cai T; Mazzoli S; Meacci F; Tinacci G; Nesi G; Zini E; Bartoletti R
    J Urol; 2007 Nov; 178(5):1906-11;discussion 1911-2. PubMed ID: 17868727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential of urinary biomarkers in early bladder cancer diagnosis.
    Lam T; Nabi G
    Expert Rev Anticancer Ther; 2007 Aug; 7(8):1105-15. PubMed ID: 18028019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical model of lifetime cost of treating bladder cancer and associated complications.
    Avritscher EB; Cooksley CD; Grossman HB; Sabichi AL; Hamblin L; Dinney CP; Elting LS
    Urology; 2006 Sep; 68(3):549-53. PubMed ID: 16979735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder.
    Karakiewicz PI; Benayoun S; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Marberger MJ; Shariat SF
    BJU Int; 2006 May; 97(5):997-1001. PubMed ID: 16542342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urine based markers of urological malignancy.
    Konety BR; Getzenberg RH
    J Urol; 2001 Feb; 165(2):600-11. PubMed ID: 11176445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
    Solsona E; Iborra I; Ricos JV; Monros JL; Rubio J; Almenar S
    J Urol; 2002 May; 167(5):2007-11. PubMed ID: 11956428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis.
    Burger M; Zaak D; Stief CG; Filbeck T; Wieland WF; Roessler W; Denzinger S
    Eur Urol; 2007 Jul; 52(1):142-7. PubMed ID: 17267099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
    Yang TB; Zeng FH; Sun ZQ
    Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluation of NMP22 in the management of bladder cancer.
    Lachaine J; Valiquette L; Crott R
    Can J Urol; 2000 Apr; 7(2):974-80. PubMed ID: 11119441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.